Carlos Martinez-Torro
Overview
Explore the profile of Carlos Martinez-Torro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bosch-Camos L, Martinez-Torro C, Lopez-Laguna H, Lascorz J, Argilaguet J, Villaverde A, et al.
Nanomaterials (Basel)
. 2024 Mar;
14(5).
PMID: 38470766
Developing prolonged antigen delivery systems that mimic long-term exposure to pathogens appears as a promising but still poorly explored approach to reach durable immunities. In this study, we have used...
2.
Serna N, Lopez-Laguna H, Aceituno P, Rojas-Pena M, Parlade E, Volta-Duran E, et al.
Pharmaceutics
. 2023 Nov;
15(11).
PMID: 38004610
Both nanostructure and multivalency enhance the biological activities of antimicrobial peptides (AMPs), whose mechanism of action is cooperative. In addition, the efficacy of a particular AMP should benefit from a...
3.
Martinez-Torro C, Alba-Castellon L, Carrasco-Diaz L, Serna N, Imedio L, Gallardo A, et al.
Biomed Pharmacother
. 2023 Jun;
164:114976.
PMID: 37276641
Two human proteins involved in the inflammatory cell death, namely Gasdermin D (GSDMD) and the Mixed Lineage Kinase Domain-Like (MLKL) protein have been engineered to accommodate an efficient ligand of...
4.
Corchero J, Favaro M, Marquez-Martinez M, Lascorz J, Martinez-Torro C, Sanchez J, et al.
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111682
By following simple protein engineering steps, recombinant proteins with promising applications in the field of drug delivery can be assembled in the form of functional materials of increasing complexity, either...
5.
de Pinho Favaro M, Atienza-Garriga J, Martinez-Torro C, Parlade E, Vazquez E, Corchero J, et al.
Microb Cell Fact
. 2022 Oct;
21(1):203.
PMID: 36199085
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and...
6.
Serna N, Falgas A, Garcia-Leon A, Unzueta U, Nunez Y, Sanchez-Chardi A, et al.
Pharmaceutics
. 2022 Jan;
14(1).
PMID: 35057088
The sustained release of small, tumor-targeted cytotoxic drugs is an unmet need in cancer therapies, which usually rely on punctual administration regimens of non-targeted drugs. Here, we have developed a...
7.
Serna N, Carratala J, Conchillo-Sole O, Martinez-Torro C, Unzueta U, Mangues R, et al.
Pharmaceutics
. 2021 Nov;
13(11).
PMID: 34834337
CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral...
8.
Martinez-Torro C, Torres-Puig S, Marcos-Silva M, Huguet-Ramon M, Munoz-Navarro C, Lluch-Senar M, et al.
Front Microbiol
. 2021 Sep;
12:695572.
PMID: 34589065
It is well-established that FtsZ drives peptidoglycan synthesis at the division site in walled bacteria. However, the function and conservation of FtsZ in wall-less prokaryotes such as mycoplasmas are less...
9.
Alamo P, Cedano J, Conchillo-Sole O, Cano-Garrido O, Alba-Castellon L, Serna N, et al.
Acta Biomater
. 2021 Jun;
130:211-222.
PMID: 34116228
Green fluorescent protein (GFP) is a widely used scaffold for protein-based targeted nanomedicines because of its high biocompatibility, biological neutrality and outstanding structural stability. However, being immunogenicity a major concern...
10.
Martinez-Torro C, Torres-Puig S, Monge M, Sanchez-Alba L, Gonzalez-Martin M, Marcos-Silva M, et al.
Emerg Microbes Infect
. 2019 Dec;
9(1):5-19.
PMID: 31859607
Transition metals participate in numerous enzymatic reactions and they are essential for survival in all living organisms. For this reason, bacterial pathogens have evolved dedicated machineries to effectively compete with...